Search for Clinical Trial Results
Essential Thrombocythemia - 25 Studies Found
Status | Study |
Recruiting |
Study Name: A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia Condition:
Date: 2009-03-17 Interventions: Drug: HDAC inhibitor (MK-0683) 400 mg once daily for 6 months |
Completed |
Study Name: Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Condition:
Date: 2010-11-11 Interventions: Drug: Imetelstat |
Terminated |
Study Name: Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia Condition:
Date: 2013-11-25 Interventions: Drug: Momelotinib Momelotinib tablet administered orally once daily |
Completed |
Study Name: Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia Condition:
Date: 2008-07-16 Interventions: Drug: LY573636-sodium Individualized dose is dependent on patient's height, weight, gender and is adjust |
Active, not recruiting |
Study Name: Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Condition:
|
Active, not recruiting |
Study Name: Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia Condition:
Date: 2008-07-29 Interventions: Drug: Ruxolitinib Ruxolitinib was administered orally and supplied as 5 mg and 25 mg tablets. |
Completed |
Study Name: Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Condition:
|
Recruiting |
Study Name: Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia Condition:
Date: 2015-03-24 Interventions:
|
Recruiting |
Study Name: The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia Condition:
Interventions:
|
Recruiting |
Study Name: The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line Condition: Essential Thrombocythemia Date: 2016-10-05 Interventions:
|